Journal article
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
Abstract
BACKGROUND: Antifungal prophylaxis with a new oral tablet formulation of posaconazole may be beneficial to patients at high risk for invasive fungal disease. A two-part (Phase 1B/3) study evaluated posaconazole tablet pharmacokinetics (PK) and safety.
METHODS: Patients with neutropenia following chemotherapy for haematological malignancy or recipients of allogeneic HSCT receiving prophylaxis or treatment for graft-versus-host disease received …
Authors
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A
Journal
Journal of Antimicrobial Chemotherapy, Vol. 71, No. 3, pp. 718–726
Publisher
Oxford University Press (OUP)
Publication Date
March 1, 2016
DOI
10.1093/jac/dkv380
ISSN
0305-7453